|1.||Ueland, Thor: 22 articles (02/2015 - 07/2002)|
|2.||Terpos, Evangelos: 21 articles (01/2014 - 08/2003)|
|3.||Aukrust, Pål: 18 articles (02/2015 - 11/2004)|
|4.||Hofbauer, Lorenz C: 18 articles (05/2014 - 08/2002)|
|5.||Dunstan, C R: 15 articles (01/2007 - 01/2000)|
|6.||Flyvbjerg, Allan: 14 articles (12/2014 - 03/2003)|
|7.||Hofbauer, L C: 13 articles (04/2012 - 01/2000)|
|8.||Kostenuik, Paul J: 12 articles (12/2015 - 12/2002)|
|9.||Schoppet, Michael: 12 articles (02/2012 - 09/2002)|
|10.||Bjerre, Mette: 11 articles (03/2015 - 08/2010)|
10/01/2001 - "Measurement of serum levels of cross-linked N-teleopeptides showed that osteoprotegerin dramatically reduced bone resorption activity in each of these experiments (P<0.001). "
04/01/2014 - "Osteoprotegerin (OPG), a potent inhibitor of osteoclastogenesis, decreases bone resorption and has protective effects on bone mineral density (BMD). "
06/01/2013 - "The aim of the present study was to determine whether osteoprotegerin (OPG) influences the bone resorption activity of osteoclasts. "
04/01/2009 - "Additional studies assessing the relative presence of receptor activator of nuclear factor kB ligand (RANKL) and its decoy receptor, osteoprotegerin (OPG), found a decrease in OPG and an increase in RANKL favoring an increase in bone resorption. "
07/01/2001 - "This study examines the ability of osteoprotegerin (OPG) to prevent the local bone resorption caused by sciatic nerve damage. "
01/01/2014 - "Osteoprotegerin CGA haplotype protection against cerebrovascular complications in anti-CCP negative patients with rheumatoid arthritis."
01/01/2015 - "The aim of this study was to investigate the regulative activity of (5R)-5-hydroxytriptolide (LLDT-8) on receptor activator of nuclear factor κ-B ligand (RANKL)/receptor activator of nuclear factor κ-B (RANK)/Osteoprotegerin (OPG) system in rheumatoid arthritis (RA) and its anti-osteoclastogenesis mechanism. "
11/01/2003 - "Decoy receptors expressed included a novel soluble form of TNFRSF25 (formerly DR3 or Apo3), implicated in rheumatoid-arthritis linkage studies, as well as osteoprotegerin, a well-characterized osteoblast protein that binds TRAIL and RANKL, and DcR2, which binds TRAIL. "
01/01/2015 - "In order to investigate the association between osteoprotegerin (OPG) gene polymorphisms and rheumatoid arthritis (RA), we studied OPG rs3102735 T/C and rs2073618 G/C polymorphisms in a Chinese Han population comprising 574 patients with RA and 804 controls. "
01/01/2015 - "Osteoprotegerin polymorphisms in Chinese Han patients with rheumatoid arthritis."
|3.||Neoplasm Metastasis (Metastasis)
08/01/2013 - "New drugs that inhibit the osteoprotegerin (OPG)/receptor activator of NF-κB ligand (RANKL)/RANK pathway have demonstrated efficacy for the treatment of bone metastasis. "
01/01/2015 - "Some recent studies have found that serum osteoprotegerin (OPG) levels may be altered in patients with bone metastasis, whereas other reports have produced inconsistent findings. "
03/01/2014 - "We aimed to assess the effect of ZA over time in patients with bone metastases by analyzing novel bone turnover marker levels including receptor activator of nuclear factor-k B ligand (RANKL) and osteoprotegerin (OPG) in serum and gingival crevicular fluid (GCF). "
01/01/2013 - "We aimed to investigate whether changes of RANKL, its inhibitor osteoprotegerin (OPG) and bone marrow-mesenchymal stromal cells (BM-MSCs) occur in PC patients without manifest bone metastases. "
01/01/2012 - "Osteoprotegerin in bone metastases: mathematical solution to the puzzle."
05/01/2014 - "Osteoprotegerin: another piece in a complex (regional pain syndrome) puzzle."
05/01/2014 - "Osteoprotegerin (OPG) is important for bone remodeling and may contribute to complex regional pain syndrome (CRPS) pathophysiology. "
05/01/2014 - "Osteoprotegerin: a new biomarker for impaired bone metabolism in complex regional pain syndrome?"
05/15/2001 - "Results indicated that osteoprotegerin treatment halted further bone destruction, reduced ongoing and movement-evoked pain, and reversed several aspects of the neurochemical reorganization of the spinal cord. "
08/01/2014 - "Osteoprotegerin reduces the development of pain behaviour and joint pathology in a model of osteoarthritis."
|5.||Bone Diseases (Bone Disease)
06/01/2014 - "The role of osteoprotegerin (OPG) in the RANK/RANKL/OPG signaling system is well defined in the myeloma bone disease. "
06/01/2014 - "C950T and C1181G osteoprotegerin gene polymorphisms in myeloma bone disease."
01/01/2012 - "Osteoprotegerin (OPG), the soluble decoy receptor of RANKL is released by bone marrow osteoblasts and plays an important role in physiological osteoblastogenesis and pathological bone disease. "
02/01/2011 - "Bone disease of osteoprotegerin deficient mouse]."
09/01/2005 - "Juvenile Paget's disease, a genetic bone disease characterized by accelerated bone turnover, results from inactivating mutations in the gene encoding osteoprotegerin--a key regulator of osteoclastogenesis. "
|2.||Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)
|3.||zoledronic acid (zoledronate)
|8.||Proteins (Proteins, Gene)
|10.||Alendronate (Alendronate Sodium)
|2.||Low-Level Laser Therapy (LLLT)
|3.||Heterologous Transplantation (Xenotransplantation)